Literature DB >> 29532791

Mechanisms of ketamine action as an antidepressant.

P Zanos1, T D Gould1,2,3.   

Abstract

Clinical studies have demonstrated that a single sub-anesthetic dose of the dissociative anesthetic ketamine induces rapid and sustained antidepressant actions. Although this finding has been met with enthusiasm, ketamine's widespread use is limited by its abuse potential and dissociative properties. Recent preclinical research has focused on unraveling the molecular mechanisms underlying the antidepressant actions of ketamine in an effort to develop novel pharmacotherapies, which will mimic ketamine's antidepressant actions but lack its undesirable effects. Here we review hypotheses for the mechanism of action of ketamine as an antidepressant, including synaptic or GluN2B-selective extra-synaptic N-methyl-D-aspartate receptor (NMDAR) inhibition, inhibition of NMDARs localized on GABAergic interneurons, inhibition of NMDAR-dependent burst firing of lateral habenula neurons, and the role of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor activation. We also discuss links between ketamine's antidepressant actions and downstream mechanisms regulating synaptic plasticity, including brain-derived neurotrophic factor (BDNF), eukaryotic elongation factor 2 (eEF2), mechanistic target of rapamycin (mTOR) and glycogen synthase kinase-3 (GSK-3). Mechanisms that do not involve direct inhibition of the NMDAR, including a role for ketamine's (R)-ketamine enantiomer and hydroxynorketamine (HNK) metabolites, specifically (2R,6R)-HNK, are also discussed. Proposed mechanisms of ketamine's action are not mutually exclusive and may act in a complementary manner to exert acute changes in synaptic plasticity, leading to sustained strengthening of excitatory synapses, which are necessary for antidepressant behavioral actions. Understanding the molecular mechanisms underpinning ketamine's antidepressant actions will be invaluable for the identification of targets, which will drive the development of novel, effective, next-generation pharmacotherapies for the treatment of depression.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29532791      PMCID: PMC5999402          DOI: 10.1038/mp.2017.255

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  196 in total

1.  Transient inactivation of the infralimbic cortex induces antidepressant-like effects in the rat.

Authors:  David A Slattery; Inga D Neumann; John F Cryan
Journal:  J Psychopharmacol       Date:  2010-06-08       Impact factor: 4.153

2.  Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects.

Authors:  Brian A Hoshaw; Jessica E Malberg; Irwin Lucki
Journal:  Brain Res       Date:  2005-03-10       Impact factor: 3.252

3.  Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine.

Authors:  Shawn E Kotermanski; Jon W Johnson
Journal:  J Neurosci       Date:  2009-03-04       Impact factor: 6.167

Review 4.  Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease.

Authors:  Akira Yoshii; Martha Constantine-Paton
Journal:  Dev Neurobiol       Date:  2010-04       Impact factor: 3.964

5.  Adaptation of cortical but not hippocampal NMDA receptors after chronic citalopram treatment.

Authors:  G Nowak; Y Li; I A Paul
Journal:  Eur J Pharmacol       Date:  1996-01-04       Impact factor: 4.432

6.  Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate.

Authors:  J D Rothstein; M Dykes-Hoberg; C A Pardo; L A Bristol; L Jin; R W Kuncl; Y Kanai; M A Hediger; Y Wang; J P Schielke; D F Welty
Journal:  Neuron       Date:  1996-03       Impact factor: 17.173

7.  Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study.

Authors:  Eric J Lenze; Elizabeth R Skidmore; Amy E Begley; John W Newcomer; Meryl A Butters; Ellen M Whyte
Journal:  Int J Geriatr Psychiatry       Date:  2011-12-16       Impact factor: 3.485

8.  Ketamine perturbs perception of the flow of time in healthy volunteers.

Authors:  Jennifer T Coull; Hannah Morgan; Victoria C Cambridge; James W Moore; Francesco Giorlando; Ram Adapa; Philip R Corlett; Paul C Fletcher
Journal:  Psychopharmacology (Berl)       Date:  2011-05-21       Impact factor: 4.530

9.  Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice.

Authors:  Hong Guo; Liching Lai; Matthew E R Butchbach; Michael P Stockinger; Xiu Shan; Georgia A Bishop; Chien-liang Glenn Lin
Journal:  Hum Mol Genet       Date:  2003-08-05       Impact factor: 6.150

10.  Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors:  Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382

View more
  169 in total

Review 1.  Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review.

Authors:  P Molero; J A Ramos-Quiroga; R Martin-Santos; E Calvo-Sánchez; L Gutiérrez-Rojas; J J Meana
Journal:  CNS Drugs       Date:  2018-05       Impact factor: 5.749

Review 2.  Glutamatergic Signaling in the Central Nervous System: Ionotropic and Metabotropic Receptors in Concert.

Authors:  Andreas Reiner; Joshua Levitz
Journal:  Neuron       Date:  2018-06-27       Impact factor: 17.173

3.  Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model.

Authors:  Kai Zhang; Hidetoh Toki; Yuko Fujita; Min Ma; Lijia Chang; Youge Qu; Shingo Harada; Tetsuhiro Nemoto; Akiko Mizuno-Yasuhira; Jun-Ichi Yamaguchi; Shigeyuki Chaki; Kenji Hashimoto
Journal:  Psychopharmacology (Berl)       Date:  2018-09-13       Impact factor: 4.530

4.  Classical conditioning of antidepressant placebo effects in mice.

Authors:  Samuel R Krimmel; Panos Zanos; Polymnia Georgiou; Luana Colloca; Todd D Gould
Journal:  Psychopharmacology (Berl)       Date:  2019-08-17       Impact factor: 4.530

5.  Ketamine Increases Proliferation of Human iPSC-Derived Neuronal Progenitor Cells via Insulin-Like Growth Factor 2 and Independent of the NMDA Receptor.

Authors:  Alessandra Grossert; Narges Zare Mehrjardi; Sarah J Bailey; Mark A Lindsay; Jürgen Hescheler; Tomo Šarić; Nicole Teusch
Journal:  Cells       Date:  2019-09-24       Impact factor: 6.600

6.  Adult neuroplasticity: A new “cure” for major depression?

Authors:  Paul R. Albert
Journal:  J Psychiatry Neurosci       Date:  2019-03-01       Impact factor: 6.186

Review 7.  Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments.

Authors:  Ronald S Duman; Gerard Sanacora; John H Krystal
Journal:  Neuron       Date:  2019-04-03       Impact factor: 17.173

Review 8.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 9.  Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.

Authors:  Saurabh S Kokane; Ross J Armant; Carlos A Bolaños-Guzmán; Linda I Perrotti
Journal:  Behav Brain Res       Date:  2020-02-13       Impact factor: 3.332

10.  NOP agonists prevent the antidepressant-like effects of nortriptyline and fluoxetine but not R-ketamine.

Authors:  Victor A D Holanda; Wilton B Santos; Laila Asth; Remo Guerrini; Girolamo Calo'; Chiara Ruzza; Elaine C Gavioli
Journal:  Psychopharmacology (Berl)       Date:  2018-08-25       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.